Tapentadol is a new drug in an old group. An overview of the use of tapentadol in the treatment of pain in cancer patients

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The pain relief is one of the most important tasks in the work of a doctor of any specialty. The patient’s pain is associated with physical suffering and negative emotional experiences. Intense acute, especially chronic, pain causes a complex of maladaptive reactions in the body. First of all, this applies to patients with malignant neoplasms, especially with cancer stage III and IV. Today, opium alkaloids and their synthetic analogues remain the most effective painkillers for intense acute and chronic pain in cancer patients. For chronic pain, strong opioids are prescribed for the second (at low doses) and third steps of pain relief. This stepwise approach is recommended by the World Health Organization. Tapentadol has become a new molecule in the opioid group. The drug was created as an alternative to tramadol, taking into account its pros and cons, which have emerged over many years of use in clinical practice. In 2008, tapentadol received FDA approval for clinical use and entered the US market. In 2010, tapentadol was approved for use in Europe. In 2014, the drug was registered in Russia under the commercial name Palexia. The article provides a literature review of the analgesic potential of tapentadol in cancer patients, a comparative assessment of the effectiveness and risks of its use with other opioid analgesics.

全文:

受限制的访问

作者简介

Mikhail Pchelintsev

Pavlov First Saint Petersburg State Medical University

编辑信件的主要联系方式.
Email: mvpchelintsev@inbox.ru
ORCID iD: 0000-0002-2582-3957
Scopus 作者 ID: 6508251228

Cand. Sci. (Med.), Associate Professor, Department of Clinical Pharmacology and Evidence-Based Medicine

俄罗斯联邦, St. Petersburg

参考

  1. Абузарова Г.Р., Алексеева Г.С., Невзорова Д.В. и др. Персонифицированная терапия, как новая стратегия лечения хронической боли в онкологии. Российский журнал боли. 2021;19(1):46–55. [Abuzarova G.R., Alekseeva G.S., Nevzoro- va D.V. Personalized therapy as a new strategy for the treatment of chronic pain in oncology. Rossiiskii zhurnal boli. 2021;19(1):46–55. (In Russ.)]. doi: 10.17116/pain20211901146.
  2. Фармакотерапия хронического болевого синдрома у взрослых пациентов при оказании паллиативной медицинской помощи в стационарных и амбулаторно-поликлинических условиях: методические рекомендации. Под ред. А.Д. Каприна. М., 2015. 67 с. [Pharmacotherapy of chronic pain syndrome in adult patients in the provision of palliative care in inpatient and outpatient settings: guidelines. Edited by A.D. Caprin. M., 2015. 67 p. (In Russ.)].
  3. Auvinen A. Prevalence of symptoms among patients with advanced cancer: an international collaborative study. Symptom Prevalence Group. J Pain Symptom Manage. 1996;12(1):3–10. doi: 10.1016/0885-3924(96)00042-5.
  4. Van den Beuken-van Everdingen M.H.J., de Rijke J.M., Kessels A.G., et al. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol. 2007;18(9):1437–49. Doi: 10.1093. /annonc/mdm056.
  5. World Health Organization. Cancer pain relief. With a guide to opioid availability. 2nd edn. Geneva, WHO. 1996. 70 p.
  6. Абузарова Г.Р. Диагностика и дифференцированная терапия хронического болевого синдрома у онкологических больных. М., 2013. 240 с. [Abuzarova G.R. Diagnosis and differentiated therapy of chronic pain syndrome in cancer patients. M., 2013. 240 p. (In Russ.)].
  7. Новиков Г.А. Контроль симптомов в паллиативной медицине. М., 2015. 248 с. [Novikov G.A. Symptom control in palliative care. M., 2015. 248 p. (In Russ.)].
  8. Штрибель Х.В. Терапия хронической боли. Практическое руководство. Перевод с нем., ред. Н.А. Осипова, А.Б. Данилова, В.В. Осипова. М., 2005. 303 с. [Striebel H.V. Therapy for chronic pain. Practical guide. Translation from German, editors N.A. Osipova, A.B. Danilova, V.V. Osipov. M., 2005. 303 p. (In Russ.)].
  9. Cancer Pain. Asstssment and manegement: ed. by E.D. Bruera, R.K. Potenoy. 2-nd edition. Cambridge Uniersity Press, 2010. 643 p.
  10. Caraceni A., Hanrs G., Kaasa S., et al. Use of opioids in the treatment of Cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012,13:e 58–68. doi: 10.1016/S1470-2045(12)70040-2.
  11. WHO guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents. Geneva: WHO, 2018.
  12. Клинические рекомендации по лечению хронического болевого синдрома у взрослых пациентов при оказании паллиативной медицинской помощи. 2022. [Clinical guidelines for the treatment of chronic pain in adult patients with palliative care. 2022. (In Russ.)]. URL: http://cr.rosminzdrav.ru.
  13. Opioids in Cancer pain. Second Edition. Mellar P. Davis, Paul Glare, Columba Quigley, Janet R. Hardy. Oxford University Press. 2009. 487 p.
  14. Сидоров А.В., Коротаева М. С. Краткая мировая история опиоидов. PALLIUM: Паллиативная и хосписная помощь. 2018;1:45–50. [Sidorov A.V., Korotaeva M. S. Brief world history of opioids. PALLIUM: Palliativnaya i khospisnaya pomoshch’. 2018;1:45–50. (In Russ.)].
  15. Абузарова Г.Р., Сарманаева Р.Р., Гамеева Е.В. Новый опиоидный анальгетик тапентадол в терапии нейропатической боли в онкологии. Медицинский совет. 2019;10:180–84. [Abuzarova G.R., Sarmanaeva R.R., Gameeva E.V. New opioid analgesic tapentadol in the treatment of neuropathic pain in oncology. Meditsinskii sovet. 2019;10:180–84. (In Russ.)]. doi: 10.21518/2079-701X-2019-10-180-184.
  16. Dean L. Tramadol Therapy and CYP2D6 Genotype, Medical Genetics Summaries. 2015.
  17. Tzschentke T.M., Christoph T., Kögel B., et al. (1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol Hydrochloride (Tapentadol HCl): a Novel mu-Opioid Receptor Agonist/Norepinephrine Reuptake Inhibitor with Broad-Spectrum Analgesic Properties. J Pharmacol Exp Ther. 2007;323:265–76. doi: 10.1124/jpet.107.126052.
  18. Tzschentke T.M., Jahnel U., Kogel B., et al. Tapentadol hydrochloride: a next-generation, centrally acting analgesic with two mechanisms of action in a single molecule. Drugs Today. 2009;45:483–96. doi: 10.1358/dot.2009.45.7.1395291.
  19. Fahad S.A. Tapentadol: A Review of Experimental Pharmacology Studies, Clinical Trials, and Recent Findings Drug Design, Development and Therapy. Drug Des Devel Ther. 2023;17:851–61. doi: 10.2147/DDDT.S402362.
  20. Колесников Ю.А., Беспалов А.Ю., Драволина О.А., Звартау Э.Э. Фармакология мю-опиоидов: пути развития. СПб., 2021. 208 с. [Kolesnikov Yu.A., Bespalov A.Yu., Dravolina O.A., Zvartau E.E. Pharmacology of mu-opioids: ways of development. St. Petersburg, 2021. 208 p. (In Russ.)].
  21. Bee L.A., Bannister K., Rahman W., Dickenson A.H. Mu-opioid and noradrenergic α(2)-adrenoceptor contributions to the effects of tapentadol on spinal electrophysiological measures of nociception in nerve-injured rats. Pain. 2011;152:131–39. doi: 10.1016/j.pain.2010.10.004.
  22. Schröder W., Tzchentke T., Terlinden R., et al. Synergistic Interaction between the Two Mechanisms of Action of Tapentadol in Analgesia. JPET. 2011;337:312–20. doi: 10.1124/jpet.110.175042.
  23. Raffa R.B., Elling C., Tzschentke T.M. Does ‘strong analgesic’ equal ‘strong opioid’? Tapentadol and the concept of ‘μ-load’. Adv Ther. 2018;35:1471–84. doi: 10.1007/s12325-018-0778-x.
  24. Freo U., Romualdi P., Kress H.G. Tapentadol for neuropathic pain: a review of clinical studies. J Pain Res. 2019;12:1537–51. doi: 10.2147/JPR.S190162.
  25. Baron R., Kern U., Muller M., et al. Effectiveness and Tolerability of a Moderate Dose of Tapentadol Prolonged Release for Managing Severe, Chronic Low Back Pain with a Neuropathic Component: An Open-label Continuation Arm of a Randomized Phase 3b Study. Pain Pract. 2014. doi: 10.1111/papr.12199.
  26. Wien P.J., Derry S., Naessens K., Bell R.F. Oral tapentadol for cancer pain. Cochrane Database Syst Rev. 2015;9(Art. No.):CD011460. doi: 10.1002/14651858. CD011460.pub2.
  27. Kress H.G., Koch E.D., Kosturski H., et al.Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain. Pain Physician 2014, 17:329–43.
  28. Kress H.G., Coluzzi F. Tapentadol in the management of cancer pain: current evidence and future perspective. J Pain Res. 2019;12:1553–60. doi: 10.2147/JPR.S191543.
  29. Carmona-Bayonas A., Paula Jiménez Fonseca P.J., Juan Virizuela Echaburu J.V. Tapentadol for Cancer Pain Management. A Narrat Rev Pain Pract. 2017;17(8):1075–88. doi: 10.1111/papr.12556.
  30. Boland J.W. Tapentadol for the management of cancer pain in adults: an update Curr Opin Supp Palliat. Care. 2023;17(2):90–7. doi: 10.1097/SPC.0000000000000641.
  31. Smith H.S. Opioids and neuropathic pain. Pain Physician. 2012;15 (Suppl. 3):ES93–110.
  32. Chen S.R., Chen H., Yuan W.X., Pan H.L. Increased presynaptic and postsynaptic α2-adrenoceptor activity in the spinal dorsal horn in painful diabetic neuropathy. J Pharmacol Exp Ther. 2011; 337(1):285–92. doi: 10.1124/jpet.110.176586.
  33. Bennett M.I., Kaasa S., Barke A., et al. The IASP classification of chronic pain for ICD-11: Chronic cancer-related pain. Pain. 2019;160:38–44. doi: 10.1097/j.pain.0000000000001363.
  34. Bennett M.I., Rayment C., Hjermstad M., et al. Prevalence and aetiology of neuropathic pain in cancer patients: A systematic review. Pain. 2012;153:359–65.
  35. Каприн А.Д. и др. Новые клинические рекомендации Всемирной Организации Здравоохранения по терапии онкологической боли у взрослых и подростков. Исследования и практика в медицине. 2021;8(2):90–108. [Kaprin A.D. New clinical guidelines of the World Health Organization for the treatment of cancer pain in adults and adolescents. Issledovaniya i praktika v meditsine. 2021;8(2):90–108. ≠≠(In Russ.)].
  36. Давыдов О.С. и др. Невропатическая боль: клинические рекомендации по диагностике и лечению Российского общества по изучению боли. Боль. 2018;4:5–41. Davydov O.S. [Neuropathic pain: clinical guidelines for the diagnosis and treatment of the Russian Society for the Study of Pain. Bol’. 2018;4:5–41. (In Russ.)].
  37. Sugiyama Y., Kataoka T., Tasaki Y., et al. Efficacy of tapentadol for first-line opioid-resistant neuropathic pain in Japan. Jpn J Clin Oncol. 2018;48(4):362–66. doi: 10.1093/jjco/hyy023.
  38. Takahara Y., Tanahashi J., Murota K., et al. Efficacy of Tapentadol for Neuropathic Pain in Cancer. Gan To Kagaku Ryoho. 2021;48(6):811–14.
  39. Galiè E., Villani V., Terrenato I., Pace A. Tapentadol in neuropathic pain cancer patients: a prospective open label study. Neurol Sci. 2017;38(10):1747–52. doi: 10.1007/s10072-017-3035-1.
  40. Cacicedo J., Ciria J.P., Morillo V., et al. Pain response and quality of life assessment in patients with moderate/severe neuropathic pain due to bone metastasis undergoing treatment with palliative radiotherapy and tapentadol: A prospective multicentre pilot study. J Med Imaging Radiat Oncol. 2020;64(6):859–65. doi: 10.1111/1754-9485.13088.
  41. Coluzzi F., Raffa R.B., Pergolizzi J. Tapentadol prolonged release for patients with multiple myeloma suffering from moderate-to-severe cancer pain due to bone disease. J Pain Res. 2015;8:229–38. doi: 10.2147/JPR.S8349.
  42. Brunetti G.A., Palumbo G., Morano G.S. Tapentadol PR for pain syndromes in real life patients with hematological malignancy. Cardiovasc. Hematol. Agents Med Chem. 2016;14:68–74. doi: 10.2174/1871525714666160405110833.
  43. Takemura M. Tapentadol in Cancer Patients with Neuropathic Pain: A Comparison of Methadone, Oxycodone, Fentanyl and Hydromorphone. Biol Pharm Bull. 2021;44:1286–93. doi: 10.1248/bpb.b21-00212.
  44. Etropolski Mi., Kelly K., Okamoto A., Rauschkolb C. Comparable efficacy and superior gastrointestinal tolerability (nausea, vomiting, constipation) of tapentadol compared with oxycodone hydrochloride. Adv Ther. 2011;28(5):401–17. doi: 10.1007/s12325-011-0018-0.
  45. Merker M., Dinges G., Koch T., et al. Undesired side effects of tapentadol in comparison to oxycodone. A meta-analysis of randomized controlled comparative studies. 2012;26(1):16–26. doi: 10.1007/s00482-011-1132-2.
  46. Kern K.-U., et al. Tapentadol versus classical WHO-III opioids for chronic back pain. Health services research study based on representative data from health insurance funds. MMW. Fortschr Med. 2022;164(Suppl. 6):19–27. doi: 10.1007/s15006-022-0876-1.
  47. Baron R. Tolerability, Safety, and Quality of Life with Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR in Patients with Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-label, Phase 3b/4. Trial Pain Pract. 2016;16(5):600–19. doi: 10.1111/papr.12361.
  48. Ignacio Velázquez Rivera I.V., Clavarana L.V., Pilar García Velasco P.G., Ramos G.M. Opioid-induced constipation in chronic pain: Experience with 180 patients. J Opioid Manag. 2019;15(1):69–76. doi: 10.5055/jom.2019.0487.
  49. Пчелинцев М.В. Оценка рисков злоупотребления тапентадолом, новым сильным опиоидом, с двойным механизмом анальгетического эффекта, обзор результатов зарубежных исследований. Паллиативная медицина и реабилитация. 2022;4:49–54. [Pchelintsev M.V. Assessment of the risks of abuse of tapentadol, a new strong opioid with a dual mechanism of analgesic effect, a review of the results of foreign studies. Palliativnaya meditsina i reabilitatsiya. 2022;4:49–54. (In Russ.)].
  50. Пчелинцев М.В. Оценка рисков злоупотребления опиоидами в условиях реальной клинической практики. Реальная клиническая практика: данные и доказательства. 2023;3(1):30–40. [Pchelintsev M.V. Assessing the risks of opioid abuse in real clinical practice. Real’naya klinicheskaya praktika: dannye i dokazatel’stva. 2023;3(1):30–40Doi. org/10.37489/2782 3784 myrwd-29. (In Russ.)].

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##